Floatz logo

Bet Bromodomain Inhibitor Zen-3694

Metastatic NUT Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Metastatic NUT Carcinoma cohort.

Asset / SponsorPhaseRating
Cudc-907
Curis, Inc.
Phase 1CC
Molibresib
GlaxoSmithKline
Phase 1CC
Abemaciclib
National Cancer Institute (NCI)
Phase 1CC
ep31670
Epigenetix, Inc.
Phase 1CC
otx015
Merck Sharp & Dohme LLC
Phase 1C
mt-4561
Tanabe Pharma America, Inc.
Phase 1/2NR

Same molecule, other indications

Bet Bromodomain Inhibitor Zen-3694 is also rated in:

Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
62 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →